The Week in Review: Reckitt Benckiser Buys Anhui’s Golong Medicine
February 23, 2013
Reckitt Benckiser, a British maker of OTC drugs, acquired Golong Medicine of Anhui, a TCM company that will provide a base for Reckitt Benckiser’s products in China; China’s SFDA announced a set of... Read More
from ChinaBio® Today
Regeneron and Bayer Start Phase III Trial of Macular Edema Drug in China
February 19, 2013
Regeneron Pharmaceuticals and Bayer HealthCare have started a new Phase III trial to test Eylea® (aflibercept) Injection as a treatment for Diabetic Macular Edema (DME). The trial will be conducted in... Read More
from ChinaBio® Today
Joinn Laboratories, a China pre-clinical CRO, is the mystery buyer of the ex-Bayer biopharma campus in the San Francisco Bay area; Fosun Pharma, executing its growth-by-acquisition strategy, paid $93... Read More
from ChinaBio® Today
Joinn Labs of China Buys Bayer’s San Francisco-Area Campus
January 08, 2013
Joinn Laboratories, a pre-clinical CRO with facilities in Beijing and Taicang, bought the major biopharma campus in the San Francisco Bay area that formerly belonged to Bayer. Joinn, which was founded... Read More
from ChinaBio® Today
A major, though still unnamed, China biopharma bought a prestigious San Francisco-area biotech campus (it formerly belonged to Bayer) and will disclose its plans for the site next month; HitGen and... Read More
from ChinaBio® Today
President and Mrs. Obama Visit Troops on Christmas Day
December 28, 2012
“Major” China Biopharma Buys Bayer's Bay-Area Biopharma Campus
December 27, 2012
A major, though as-yet unnamed, China biopharma has bought the prestigious San Francisco-area biotech campus that formerly belonged to Bayer. The six-building campus is located in Richmond, on the... Read More
from ChinaBio® Today
The Week in Review: Huapont Pharma Raises $146 Million
March 31, 2012
Chongqing Huapont Pharma plans to raise $146 million in a private placement to fund four capital projects; Lee's Pharmaceutical signed a term sheet with RegeneRx to in-license the China rights for... Read More
from ChinaBio® Today
Bayer HealthCare has extended its research partnership with Beijing’s Tsinghua University for another three years. In 2009, the two parties established the Bayer-Tsinghua Joint Research Center for... Read More
from ChinaBio® Today
Last week, Roche said it would “significantly” reduce the price the company charges in India for two expensive biotech cancer drugs – Herceptin and MabThera (known as Rituxin in the US). The move came... Read More
from ChinaBio® Today
The Week in Review: China’s 12th Five-year Plan for Medical Technology
December 03, 2011
China released its 12th Five-year Plan for Medical Technology, setting a long list of broad goals to be accomplished by the end of 2015; the World Health Organization certified the quality of the... Read More
from ChinaBio® Today
Regeneron/Bayer Start China Trial of Wet AMD Drug
November 28, 2011
Regeneron Pharma and Bayer have begun a China Phase III trial of Eylea™ (aflibercept) Injection, a treatment for neovascular age-related macular degeneration (wet AMD). Earlier this month, Eylea was... Read More
from ChinaBio® Today
The Week in Review: Huge China Hi-Tech Stimulus Rumored
November 26, 2011
According to reports, China will invest $1.7 trillion over the next five years in five strategic industries, including biotechnology, though the program has never been officially confirmed; Fosun... Read More
from ChinaBio® Today
A Second Life for Bayer’s Diabetes Drug in China
November 23, 2011
China offers many different opportunities to global pharma – inexpensive APIs, drug development, a large market, to name a few very broad categories. For Bayer, China has given a second life to a... Read More
from ChinaBio® Today
Bayer says Xarelto prevents heart attacks
September 30, 2011
FRANKFURT, Sept 30 (Reuters) - German drugmaker Bayer said its potential blockbuster drug Xarelto was shown to prevent heart attacks in patients that have already suffered one. Read More
category
companyNews
European Factors-Shares seen down, eyes on German EFSF vote
September 29, 2011
LONDON, Sept 29 (Reuters) - European shares are set to extend the previous session's steep losses on Thursday and on track to post the worst quarter in almost three years, with investors seen cautious... Read More
category
companyNews
UPDATE 1-Astellas halts development of anti-clotting drug
September 28, 2011
category
companyNews
UPDATE 1-US FDA remains wary of drospirenone clot risk
September 26, 2011
* Remains concerned but not reached a conclusion - FDA (Adds Bayer's comments in paragraph 5 and 6) Read More
category
companyNews
Bayer wins key EU recommendation for Xarelto
September 23, 2011
FRANKFURT, Sept 23 (Reuters) - European regulators recommended approval of Bayer's biggest pipeline drug Xarelto for use in the mass market of stroke prevention. Read More
category
companyNews
Bayer to reshuffle diagnostics business
September 16, 2011
FRANKFURT, Sept 16 (Reuters) - German drugmaker Bayer is to overhaul its contrast agents business, seeking marketing synergies with its U.S. medical devices unit Medrad, as it cuts costs to counter... Read More
category
companyNews
European shares fall on U.S. recession worries
September 09, 2011
LONDON, Sept 9 (Reuters) - European shares fell on Friday morning, tracking Wall Street lower on investors' worries that U.S policymakers were not acting strongly enough prevent the world's biggest... Read More
category
companyNews
German stocks - Factors to watch on September 9
September 09, 2011
FRANKFURT, Sept 9 (Reuters) - The following are some of the factors that may move German stocks on Friday: Read More
category
companyNews
UPDATE 1-US FDA panel gives nod to Bayer/J&J anti-clot drug
September 08, 2011
category
companyNews
European shares hit 2-yr closing low as banks fall
September 06, 2011
category
companyNews
UPDATE 1-US FDA questions whether Bayer-J&J drug effective
September 06, 2011
WASHINGTON, Sept 6 (Reuters) - U.S. drug regulators questioned the effectiveness of an experimental stroke preventer from Bayer and Johnson & Johnson , sending Bayer shares down more than 9 percent. Read More
category
companyNews
US FDA questions whether Bayer, J&J drug effective
September 06, 2011
WASHINGTON, Sept 6 (Reuters) - U.S. drug regulators questioned the effectiveness of an experimental stroke preventer from Bayer and Johnson & Johnson . Read More
category
companyNews
Thailand - Market factors to watch - Sept 6
September 05, 2011
BANGKOK, Sept 6 (Reuters) - Thai stocks are expected to fall on Tuesday as several big-cap stocks trade ex-dividend, with broader market sentiment weak on fears over Europe's sovereign debt troubles. Read More
category
companyNews
Astellas clot drug raises bleeding in heart study
August 30, 2011
PARIS, Aug 30 (Reuters) - An experimental anti-clotting drug from Japan's Astellas increased bleeding two- to four-fold in a mid-stage clinical study of heart patients, raising questions about its role... Read More
category
companyNews
UPDATE 1-New Bristol, Pfizer clot drug saves lives in study
August 28, 2011
* Rival to products from Bayer/J&J and Boehringer (Adds further comment from doctors, analysts) Read More
category
companyNews
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here